IP Verse

Isis Pharmaceuticals competitive analysis

Latest publications and patents of Isis Pharmaceuticals New

Explore the latest publications and patents granted to Isis Pharmaceuticals, showcasing their recent innovations and technological advancements.

Last updated on: Sep 27, 2025
Publication NumberPublication DateTitleLegal Status

Get instant update for new patents of Isis Pharmaceuticals

EP2906696
Dec 14, 2022Methods For Modulating C9Orf72 ExpressionPatent Maintained As Amended
EP2742135
Jun 10, 2020Linkage Modified Gapped Oligomeric Compounds And Uses ThereofPatent Maintained As Amended
EP2399588
Apr 29, 2020Nucleoside Derivatives As Inhibitors Of Rna-Dependent Rna Viral PolymeraseRevoked
EP2640853
Dec 26, 2018Modulation Of Alpha Synuclein ExpressionRevoked
EP2864479
Aug 15, 2018Modulation Of Ube3A-Ats ExpressionRevoked
EP2701713
Feb 7, 2018Modulation Of Apolipoprotein Ciii (Apociii) ExpressionRevoked
EP2282744
Jan 17, 2018Oligomeric Compounds Comprising Tricyclic Nucleosides And Methods For Their UseNo Opposition Filed Within Time Limit
EP2839006
Jan 3, 2018Oligomeric Compounds Comprising Bicyclic Nucleotides And Uses ThereofNo Opposition Filed Within Time Limit
EP2812342
Nov 15, 2017Modulation Of Rna By Repeat TargetingRevoked

Latest patents of Isis Pharmaceuticals opposed by its competitors

Explore Isis Pharmaceuticals's recently opposed patents, revealing key competitive challenges and strategic patent disputes in the industry. Track oppositions filed by competitors to understand technology battlegrounds and assess potential risks.

Last updated on: Oct 2, 2025
Patent NumberGrant DateTitleTotal Oppositions
EP2906696
Dec 14, 2022Methods For Modulating C9Orf72 Expression2
EP2742135
Jun 10, 2020Linkage Modified Gapped Oligomeric Compounds And Uses Thereof1
EP2399588
Apr 29, 2020Nucleoside Derivatives As Inhibitors Of Rna-Dependent Rna Viral Polymerase1
EP2640853
Dec 26, 2018Modulation Of Alpha Synuclein Expression1
EP2864479
Aug 15, 2018Modulation Of Ube3A-Ats Expression1
EP2701713
Feb 7, 2018Modulation Of Apolipoprotein Ciii (Apociii) Expression2
EP2812342
Nov 15, 2017Modulation Of Rna By Repeat Targeting1

Latest PTAB cases involving Isis Pharmaceuticals

Discover the latest PTAB cases involving Isis Pharmaceuticals, highlighting their recent legal challenges and patent disputes.

Peer Comparison New

IP litigation analysis comparing Isis Pharmaceuticals with top 3 competitors. Includes complete PTAB case data and opposition data from 2018 onwards.

Last updated on: Oct 2, 2025
CompanyOppositions FiledOppositions FacedPTAB Cases FiledPTAB Cases FacedStrategy Type
ISIS PHARMACEUTICALS - 9 - - Non-Active
HOFFMANN EITLE147 - - - Highly Aggressive
ROCHE372534Aggressive
STRAWMAN331 - - - Highly Aggressive